<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2020-03-03</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NOTES FROM PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ ОПЫТ</subject></subj-group></article-categories><title-group><article-title>The Capabilities of Amlodipine/Lisinopril Single-Pill Combination in the Treatment of Newly Diagnosed Arterial Hypertension in a Middle-Aged Patient (Case Report)</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности фиксированной комбинации амлодипин/лизиноприл в лечении впервые выявленной артериальной гипертензии у пациентки среднего возраста (клинический пример)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кочетков</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kochetkov</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кочетков Алексей Иванович – кандидат медицинских наук, доцент, кафедра терапии и полиморбидной патологии</p><p>125993, Москва, ул. Баррикадная, 2/1 </p></bio><bio xml:lang="en"><p>Alexey I. Kochetkov – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology</p><p>Barrikadnaya ul. 2/1, Moscow, 125993 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лопухина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lopukhina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лопухина Мария Вадимовна – кандидат медицинских наук, заведующая отделением функциональной диагностики</p><p>111399, Москва, Федеративный проспект, 17 </p></bio><bio xml:lang="en"><p>Mariya V. Lopukhina – MD, PhD, Head of Department of Functional Diagnostics</p><p>Federativnii pr. 17, Moscow, 111399 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котаева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotaeva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Котаева Елена Александровна – кандидат медицинских наук, зав. кардиологическим отделением №5</p><p>125284, Москва, 2-й Боткинский пр-д, 5 </p></bio><bio xml:lang="en"><p>Elena A. Kotaeva – MD, PhD, Head of Cardiology Department №5</p><p>Vtoroi Botkinskii pr. 5, Moscow, 125284</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кириченко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirichenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кириченко Андрей Аполлонович – доктор медицинских наук, профессор, кафедра терапии и полиморбидной патологии</p><p>125993, Москва, ул. Баррикадная, 2/1 </p></bio><bio xml:lang="en"><p>Andrey A. Kirichenko – MD, PhD, Professor, Chair of Therapy and Polymorbid Pathology</p><p>Barrikadnaya ul. 2/1, Moscow, 125993 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остроумова</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostroumova</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Остроумова Ольга Дмитриевна – доктор медицинских наук, профессор, зав. кафедрой терапии и полиморбидной патологии, РМАНПО; профессор, кафедра клинической фармакологии и пропедевтики внутренних болезней, Сеченовский университет</p><p>125993, Москва, ул. Баррикадная, 2/1, </p><p>119991, Москва, ул. Трубецкая, 8 стр. 2 </p></bio><bio xml:lang="en"><p>Olga D. Ostroumova – MD, PhD, Professor, Head of Chair of Therapy and Polymorbid Pathology, Russian Medical Academy of Continuous Professional Education; Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Medicine, Sechenov University</p><p>Barrikadnaya ul. 2/1, Moscow, 125993, </p><p>Trubetskaya ul. 8-2, Moscow, 119991</p></bio><email xlink:type="simple">ostroumova.olga@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская клиническая больница им. Е.О. Мухина</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E.O. Mukhin Municipal Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Городская клиническая больница имени С.П. Боткина</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S.P. Botkin Municipal Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования;&#13;
Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education;&#13;
I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>01</day><month>05</month><year>2020</year></pub-date><volume>16</volume><issue>2</issue><fpage>221</fpage><lpage>230</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kochetkov A.I., Lopukhina M.V., Kotaeva E.A., Kirichenko A.A., Ostroumova O.D., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Кочетков А.И., Лопухина М.В., Котаева Е.А., Кириченко А.А., Остроумова О.Д.</copyright-holder><copyright-holder xml:lang="en">Kochetkov A.I., Lopukhina M.V., Kotaeva E.A., Kirichenko A.A., Ostroumova O.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2176">https://www.rpcardio.online/jour/article/view/2176</self-uri><abstract><p>Arterial hypertension (AH) is one of the most significant modifiable risk factors that increase cardiovascular morbidity and mortality worldwide, including Russia. The complex of structural and functional changes in the heart that occurs during AH consists not only in the formation of left ventricular (LV) myocardial hypertrophy, but also in the myocardial stiffness increasing due to collagen formation and cardiomyocytes apoptosis. These abnormalities are substrate for diastolic function disturbances, electrical myocardial instability and ischemia. The article provides a clinical case of amlodipine/lisinopril single-pill combination (A/L SPC) use in real clinical practice in a patient with stage II grade 2 newly diagnosed AH and its effect on blood pressure and echocardiographic myocardial fibrosis markers, including speckle tracking parameters The high antihypertensive efficacy of A/L SPC, a favorable effect on blood pressure circadian rhythm, as well as pronounced target-organ protective properties, in particular the ability to reduce LV and left atrial stiffness, were demonstrated. So, we conclude that A/L SPC improve the elastic properties of the left heart.</p></abstract><trans-abstract xml:lang="ru"><p>Артериальная гипертония (АГ) является одним из наиболее значимых модифицируемых факторов риска, увеличивающих сердечно-сосудистую заболеваемость и смертность во всем мире, в том числе, и в Российской Федерации. Комплекс структурно-функциональных изменений в сердце, возникающих при АГ, заключается не только в формировании гипертрофии миокарда левого желудочка (ЛЖ), но и в повышении жесткости сердечной мышцы за счет коллагенообразования и апоптоза кардиомиоцитов, что в свою очередь является субстратом для нарушения диастолической функции, электрической нестабильности миокарда и потенцирует его ишемию. В статье приведен пример использования фиксированной комбинации амлодипин/лизиноприл (ФК А/Л) в реальной клинической практике у пациентки с впервые выявленной АГ II стадии 2 степени и ее влияния на уровень артериального давления и эхокардиографические маркеры нарушения упруго-эластических свойств миокарда, в том числе, с применением методики Speckle Tracking. Продемонстрирована высокая антигипертензивная эффективность ФК А/Л, благоприятное влияние на суточный профиль артериального давления, а также выраженные органопротективные свойства, в частности, способность снижать жесткость миокарда ЛЖ и левого предсердия, и тем самым улучшать упруго-эластические свойства левых отделов сердца.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>эхокардиография</kwd><kwd>speckle tracking</kwd><kwd>суточное мониторирование артериального давления</kwd><kwd>жесткость миокарда</kwd><kwd>фиксированные комбинации антигипертензивных препаратов</kwd><kwd>амлодипин</kwd><kwd>лизиноприл</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>echocardiography</kwd><kwd>speckle tracking</kwd><kwd>ambulatory blood pressure monitoring</kwd><kwd>myocardial stiffness</kwd><kwd>single-pill combinations</kwd><kwd>amlodipine</kwd><kwd>lisinopril</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31. DOI:10.26442/2075082X.2019.1.190179.</mixed-citation><mixed-citation xml:lang="en">Chazova I.E., Zhernakova Y.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (In Russ.) DOI:10.26442/2075082X.2019.1.190179.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pavlopoulos H., Nihoyannopoulos P. The constellation of hypertensive heart disease. Hellenic J Cardiol. 2008;49(2):92-9.</mixed-citation><mixed-citation xml:lang="en">Pavlopoulos H., Nihoyannopoulos P. The constellation of hypertensive heart disease. Hellenic J Cardiol. 2008;49(2):92-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906. DOI:10.1016/S0140-6736(05)67185-1.</mixed-citation><mixed-citation xml:lang="en">Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906. DOI:10.1016/S0140-6736(05)67185-1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jamerson K., Weber M.A., Bakris G.L., et al; ACCOMPLISH Trial Investigators. Benazepril plus Amlodipine or hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med. 2008;359(23):2417-28. DOI:10.1056/NEJMoa0806182.</mixed-citation><mixed-citation xml:lang="en">Jamerson K., Weber M.A., Bakris G.L., et al; ACCOMPLISH Trial Investigators. Benazepril plus Amlodipine or hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med. 2008;359(23):2417-28. DOI:10.1056/NEJMoa0806182.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lang R.M., Badano L.P., Mor-Avi V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. DOI:10.1016/j.echo.2014.10.003.</mixed-citation><mixed-citation xml:lang="en">Lang R.M., Badano L.P., Mor-Avi V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. DOI:10.1016/j.echo.2014.10.003.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kahan T. The importance of myocardial fibrosis in hypertensive heart disease. J Hypertens. 2012;30(4):685-687. DOI:10.1097/HJH.0b013e328350e5db.</mixed-citation><mixed-citation xml:lang="en">Kahan T. The importance of myocardial fibrosis in hypertensive heart disease. J Hypertens. 2012;30(4):685-687. DOI:10.1097/HJH.0b013e328350e5db.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jellis C., Martin J., Narula J., Marwick T.H. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56(2):89-97. DOI:10.1016/j.jacc.2010.02.047.</mixed-citation><mixed-citation xml:lang="en">Jellis C., Martin J., Narula J., Marwick T.H. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56(2):89-97. DOI:10.1016/j.jacc.2010.02.047.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Biering-Sørensen T., Biering-Sørensen S.R., Olsen F.J., et al. Global Longitudinal Strain by Echocardiography Predicts Long-Term Risk of Cardiovascular Morbidity and Mortality in a Low-Risk General Population: The Copenhagen City Heart Study. Circ Cardiovasc Imaging. 2017;10(3): pii: e005521. DOI:10.1161/CIRCIMAGING.116.005521.</mixed-citation><mixed-citation xml:lang="en">Biering-Sørensen T., Biering-Sørensen S.R., Olsen F.J., et al. Global Longitudinal Strain by Echocardiography Predicts Long-Term Risk of Cardiovascular Morbidity and Mortality in a Low-Risk General Population: The Copenhagen City Heart Study. Circ Cardiovasc Imaging. 2017;10(3): pii: e005521. DOI:10.1161/CIRCIMAGING.116.005521.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Monaster S., Ahmad M., Braik A. Comparison between strain and strain rate in hypertensive patients with and without left ventricular hypertrophy: a speckle-tracking study. Menoufia Medical Journal. 2014;27(2):322.</mixed-citation><mixed-citation xml:lang="en">Monaster S., Ahmad M., Braik A. Comparison between strain and strain rate in hypertensive patients with and without left ventricular hypertrophy: a speckle-tracking study. Menoufia Medical Journal. 2014;27(2):322.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Parati G., Stergiou G., O'Brien E., et al; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66. DOI:10.1097/HJH.0000000000000221.</mixed-citation><mixed-citation xml:lang="en">Parati G., Stergiou G., O'Brien E., et al; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66. DOI:10.1097/HJH.0000000000000221.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ерш И.Р., Зайцев В.И., Романчук Э.В и др. Эффективность длительной терапии препаратом Экватор больных артериальной гипертензией в амбулаторных условиях. Международные Обзоры: Клиническая Практика и Здоровье. 2014;2(8):74-86.</mixed-citation><mixed-citation xml:lang="en">Ersh I.R., Zaicev V.I., Romanchuk E.V., et al. Efficacy of long-term therapy with the Equator in patients with arterial hypertension in ambulatory conditions. Mezhdunarodnye Obzory: Klinicheskaya Praktika I Zdorov’e 2014;2(8):74-86. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Донская А.А. Морозов С.Н., Морозова Е.А. Оценка влияния монотерапии Экватором на гемодинамические показатели у лиц с артериальной гипертонией. Кардиоваскулярная Терапия и Профилактика. 2008;6(4)Приложение 2:37.</mixed-citation><mixed-citation xml:lang="en">Donskaja A.A., Morozov S.N., Morozova E.A. Evaluation of the effect of monotherapy with the Equator on hemodynamic parameters in persons with arterial hypertension. Kardiovaskulyarnaya terapiya i profilaktika 2008;№ 6(4)Suppl.2:37 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Maceira A.M., Mohiaddin R.H. Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson. 2012;14:28. DOI:10.1186/1532-429X-14-28.</mixed-citation><mixed-citation xml:lang="en">Maceira A.M., Mohiaddin R.H. Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson. 2012;14:28. DOI:10.1186/1532-429X-14-28.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">de Simone G., Devereux R.B., Koren M.J., et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation. 1996;93:259-65. DOI:10.1161/01.cir.93.2.259.</mixed-citation><mixed-citation xml:lang="en">de Simone G., Devereux R.B., Koren M.J., et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation. 1996;93:259-65. DOI:10.1161/01.cir.93.2.259.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Melenovsky V., Borlaug B.A., Rosen B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207. DOI:10.1016/j.jacc.2006.08.050</mixed-citation><mixed-citation xml:lang="en">Melenovsky V., Borlaug B.A., Rosen B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207. DOI:10.1016/j.jacc.2006.08.050</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Borlaug B.A., Lam C.S., Roger V.L., et al. Contractility and ventricular systolic stiffening in hypertensive heart disease. Insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54:410-8. DOI:10.1016/j.jacc.2009.05.013.</mixed-citation><mixed-citation xml:lang="en">Borlaug B.A., Lam C.S., Roger V.L., et al. Contractility and ventricular systolic stiffening in hypertensive heart disease. Insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54:410-8. DOI:10.1016/j.jacc.2009.05.013.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mizuguchi Y., Oishi Y., Miyoshi H., et al. The functional role of longitudinal, circumferential, and radial myocardial deformation for regulating the early impairment of left ventricular contraction and relaxation in patients with cardiovascular risk factors: a study with two-dimensional strain imaging. J Am Soc Echocardiogr. 2008;21:1138-44. DOI:10.1016/j.echo.2008.07.016.</mixed-citation><mixed-citation xml:lang="en">Mizuguchi Y., Oishi Y., Miyoshi H., et al. The functional role of longitudinal, circumferential, and radial myocardial deformation for regulating the early impairment of left ventricular contraction and relaxation in patients with cardiovascular risk factors: a study with two-dimensional strain imaging. J Am Soc Echocardiogr. 2008;21:1138-44. DOI:10.1016/j.echo.2008.07.016.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Oishi Y., Miyoshi H., Iuchi A., et al. Negative impact of cardiovascular risk factors on left atrial and left ventricular function related to aortic stiffness-new application of 2-dimensional speckle-tracking echocardiography. Circ J. 2013;77:1490-8. DOI:10.1253/circj.CJ-12-1260.</mixed-citation><mixed-citation xml:lang="en">Oishi Y., Miyoshi H., Iuchi A., et al. Negative impact of cardiovascular risk factors on left atrial and left ventricular function related to aortic stiffness-new application of 2-dimensional speckle-tracking echocardiography. Circ J. 2013;77:1490-8. DOI:10.1253/circj.CJ-12-1260.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Morris D.A., Gailani M., Vaz Pérez A., et al. Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. J Am Soc Echocardiogr. 2011;24:651-62. DOI:10.1016/j.echo.2011.02.004.</mixed-citation><mixed-citation xml:lang="en">Morris D.A., Gailani M., Vaz Pérez A., et al. Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. J Am Soc Echocardiogr. 2011;24:651-62. DOI:10.1016/j.echo.2011.02.004.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mondillo S., Cameli M., Caputo M.L., et al. Early detection of left atrial strain abnormalities by speckletracking in hypertensive and diabetic patients with normal left atrial size. J Am Soc Echocardiogr. 2011;24:898-908. DOI:10.1016/j.echo.2011.04.014.</mixed-citation><mixed-citation xml:lang="en">Mondillo S., Cameli M., Caputo M.L., et al. Early detection of left atrial strain abnormalities by speckletracking in hypertensive and diabetic patients with normal left atrial size. J Am Soc Echocardiogr. 2011;24:898-908. DOI:10.1016/j.echo.2011.04.014.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Manaka M., Tanaka N., Takei Y., et al. Assessment of regional myocardial systolic function in hypertensive left ventricular hypertrophy using harmonic myocardial strain imaging. J Cardiol. 2005;45:53- 60.</mixed-citation><mixed-citation xml:lang="en">Manaka M., Tanaka N., Takei Y., et al. Assessment of regional myocardial systolic function in hypertensive left ventricular hypertrophy using harmonic myocardial strain imaging. J Cardiol. 2005;45:53- 60.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Santos M., Shah A.M. Alterations in cardiac structure and function in hypertension. Curr Hypertens Rep. 2014;16(5):428. DOI:10.1007/s11906-014-0428-x.</mixed-citation><mixed-citation xml:lang="en">Santos M., Shah A.M. Alterations in cardiac structure and function in hypertension. Curr Hypertens Rep. 2014;16(5):428. DOI:10.1007/s11906-014-0428-x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Gosse P. Left ventricular hypertrophy-the problem and possible solutions. J Int Med Res. 2005;33 Suppl 1:3A-11A. DOI:10.1177/14732300050330S102.</mixed-citation><mixed-citation xml:lang="en">Gosse P. Left ventricular hypertrophy-the problem and possible solutions. J Int Med Res. 2005;33 Suppl 1:3A-11A. DOI:10.1177/14732300050330S102.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kang S.J., Lim H.S., Choi B.J., et al. Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension. J Am Soc Echocardiogr. 2008;21(8):907-11. DOI:10.1016/j.echo.2008.01.015.</mixed-citation><mixed-citation xml:lang="en">Kang S.J., Lim H.S., Choi B.J., et al. Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension. J Am Soc Echocardiogr. 2008;21(8):907-11. DOI:10.1016/j.echo.2008.01.015.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Krämer J, Niemann M, Liu D et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J. 2013;34(21):1587-96. DOI:10.1093/eurheartj/eht098.</mixed-citation><mixed-citation xml:lang="en">Krämer J, Niemann M, Liu D et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J. 2013;34(21):1587-96. DOI:10.1093/eurheartj/eht098.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ishizu T., Seo Y., Kameda Y., et al. Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease. Hypertension. 2014;63(3):500-6. DOI:10.1161/HYPERTENSIONAHA.113.02149.</mixed-citation><mixed-citation xml:lang="en">Ishizu T., Seo Y., Kameda Y., et al. Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease. Hypertension. 2014;63(3):500-6. DOI:10.1161/HYPERTENSIONAHA.113.02149.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Остроумова О.Д., Кочетков А.И. Влияние фиксированной комбинации амлодипин/лизиноприл на выраженность гипертрофии и показатели жесткости миокарда у пациентов с гипертонической болезнью. Кардиология. 2016;56(11):27-37. DOI:10.18565/cardio.2016.11.27-37.</mixed-citation><mixed-citation xml:lang="en">Ostroumova O.D., Kochetkov A.I. Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension Kardiologiia. 2016;56(11):27-37 (In Russ.)  DOI:10.18565/cardio.2016.11.27-37.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Остроумова О.Д., Кочетков А.И., Лопухина М.В. Сравнительный анализ эффективности фиксированных комбинаций амлодипин/лизиноприл и бисопролол/гидрохлоротиазид у пациентов с гипертонической болезнью в сочетании с ожирением и избыточной массой тела. Рациональная Фармакотерапия в Кардиологии. 2017;13(4):443-53. DOI:10.20996/1819-6446-2017-13-4-443-453.</mixed-citation><mixed-citation xml:lang="en">Ostroumova O.D., Kochetkov A.I., Lopukhina M.V. Comparative Analysis of the Efficacy of FixedDose Combinations of Amlodipine/Lisinopril and Bisoprolol/Hydrochlorthiazide in Patients with Essential Arterial Hypertension Combined with Obesity and Overweight. Rational Pharmacotherapy in Cardiology. 2017;13(4):443-53 (In Russ.)  DOI:10.20996/1819-6446-2017-13-4-443-453.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Остроумова О.Д., Кочетков А.И., Копченов И.И., Фомина В.М. Артериальная гипертония в сочетании с избыточной массой тела и ожирением. Возможности комбинации амлодипина и лизиноприла. Часть 1. Особенности суточного профиля артериального давления и поражения сердца как органа-мишени у больных с артериальной гипертонией в сочетании с избыточной массой тела и ожирением. Рациональная Фармакотерапия в Кардиологии. 2017;13(5):693-8. DOI:10.20996/1819-6446-2017-13-5-693-698.</mixed-citation><mixed-citation xml:lang="en">Ostroumova O.D., Kochetkov A.I., Kopchjonov I.I., Fomina V.M. Arterial Hypertension in the Presence of Overweight and Obesity. The Capabilities of Amlodipine and Lisinopril Combination. Part 1. Features of the Daily profile of Blood Pressure and Heart Damage as a Target Organ in Patients with Arterial Hypertension in Combination with Overweight and Obesity. Rational Pharmacotherapy in Cardiology. 2017;13(5):693-8 (In Russ.) DOI:10.20996/1819-6446-2017-13-5-693-698.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Остроумова О.Д., Кочетков А.И., Копченов И.И., Фомина В.М. Артериальная гипертония в сочетании с избыточной массой тела и ожирением. возможности комбинации амлодипина и лизиноприла. Часть 2. Антигипертензивные и органопротективные эффекты фиксированной комбинации амлодипин/лизиноприл у больных с артериальной гипертонией в сочетании с избыточной массой тела и ожирением. Рациональная Фармакотерапия в Кардиологии. 2017;13(6):841-50. DOI:10.20996/1819-6446-2017-13-6-841-850.</mixed-citation><mixed-citation xml:lang="en">Ostroumova O.D., Kochetkov A.I., Kopchjonov I.I., Fomina V.M. Arterial Hypertension in the Presence of Overweight and Obesity. The Capabilities of Amlodipine and Lisinopril Combination. Part 2. Antihypertensive and Organoprotective Effects of Amlodipine/Lisinopril Fixed-Dose Combination in Patients with Arterial Hypertension in the Presence of Overweight and Obesity. Rational Pharmacotherapy in Cardiology. 2017;13(6):841-50 (In Russ.) DOI:10.20996/1819-6446-2017-13-6-841-850.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Остроумова О.Д., Кочетков А.И. Эффективность фиксированной комбинации амлодипин/лизиноприл у курящих пациентов с артериальной гипертонией. Системные Гипертензии. 2018;15(1):23-31. DOI:10.26442/2075-082X_15.1.23-31.</mixed-citation><mixed-citation xml:lang="en">Ostroumova O.D., Kochetkov A.I. Fixed combination of amlodipine and lisinopril effectiveness in hypertensive smokers. Systemic Hypertension. 2018;15(1):23-31 (In Russ.) DOI:10.26442/2075-082X_15.1.23-31.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-93. DOI:10.1161/01.CIR.102.12.1388.</mixed-citation><mixed-citation xml:lang="en">Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-93. DOI:10.1161/01.CIR.102.12.1388.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Tsang T.S., Barnes M.E., Abhayaratna W.P., et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol. 2006;97:916-20. DOI:10.1016/j.amjcard.2005.09.143.</mixed-citation><mixed-citation xml:lang="en">Tsang T.S., Barnes M.E., Abhayaratna W.P., et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol. 2006;97:916-20. DOI:10.1016/j.amjcard.2005.09.143.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Diez J., Laviades C., Mayor G., et al. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation. 1995;91:1450-6. DOI:10.1161/01.CIR.91.5.1450.</mixed-citation><mixed-citation xml:lang="en">Diez J., Laviades C., Mayor G., et al. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation. 1995;91:1450-6. DOI:10.1161/01.CIR.91.5.1450.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101(14):1729-35. DOI:10.1161/01.cir.101.14.1729.</mixed-citation><mixed-citation xml:lang="en">Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101(14):1729-35. DOI:10.1161/01.cir.101.14.1729.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez B., Querejeta R., Varo N. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antuhypertensive treatment in hypertensive patients. Circulation 2001;104:286-91. DOI:10.1161/01.CIR.104.3.286.</mixed-citation><mixed-citation xml:lang="en">Lopez B., Querejeta R., Varo N. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antuhypertensive treatment in hypertensive patients. Circulation 2001;104:286-91. DOI:10.1161/01.CIR.104.3.286.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Varo N., Iraburu M., Varela M., et al. Chronic AT (1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000;35(6):1197-202. DOI:10.1161/01.hyp.35.6.1197.</mixed-citation><mixed-citation xml:lang="en">Varo N., Iraburu M., Varela M., et al. Chronic AT (1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000;35(6):1197-202. DOI:10.1161/01.hyp.35.6.1197.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Li H., Simon H., Bocan T., Peterson J. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-I inhibition. Cardiovasc Res. 2000;46:298-306. DOI:10.1016/s0008-6363(00)00028-6.</mixed-citation><mixed-citation xml:lang="en">Li H., Simon H., Bocan T., Peterson J. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-I inhibition. Cardiovasc Res. 2000;46:298-306. DOI:10.1016/s0008-6363(00)00028-6.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Xing S.S., Tan H.W., Bi X.P., et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med. 2008;14(7-8):395-402. DOI:10.2119/2008-00024.Xing.</mixed-citation><mixed-citation xml:lang="en">Xing S.S., Tan H.W., Bi X.P., et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med. 2008;14(7-8):395-402. DOI:10.2119/2008-00024.Xing.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Siddesha J.M., Valente A.J., Sakamuri S.S., et al. Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J Cell Physiol. 2014;229(7):845-55. DOI:10.1002/jcp.24511.</mixed-citation><mixed-citation xml:lang="en">Siddesha J.M., Valente A.J., Sakamuri S.S., et al. Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J Cell Physiol. 2014;229(7):845-55. DOI:10.1002/jcp.24511.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumori A., Nunokawa Y., Sasayama S. Nifedipine inhibits activation of transcription factor NFkappaB. Life Sci. 2000;67:2655-61. DOI:10.1016/s0024-3205(00)00849-3.</mixed-citation><mixed-citation xml:lang="en">Matsumori A., Nunokawa Y., Sasayama S. Nifedipine inhibits activation of transcription factor NFkappaB. Life Sci. 2000;67:2655-61. DOI:10.1016/s0024-3205(00)00849-3.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Iwasaki Y., Asai M., Yoshida M., et al. Nilvadipine inhibits nuclear factor-kappaB-dependent transcription in hepatic cells. Clin. Chim. Acta. 2004;350:151-7. DOI:10.1016/j.cccn.2004.07.012.</mixed-citation><mixed-citation xml:lang="en">Iwasaki Y., Asai M., Yoshida M., et al. Nilvadipine inhibits nuclear factor-kappaB-dependent transcription in hepatic cells. Clin. Chim. Acta. 2004;350:151-7. DOI:10.1016/j.cccn.2004.07.012.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Matsubara M., Hasegawa K. Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur J Pharmacol. 2004;498:303-14. DOI:10.1016/j.ejphar.2004.07.086.</mixed-citation><mixed-citation xml:lang="en">Matsubara M., Hasegawa K. Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur J Pharmacol. 2004;498:303-14. DOI:10.1016/j.ejphar.2004.07.086.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
